Pihoker C, Badger T M, Reynolds G A, Bowers C Y
Department of Pediatrics, University of Washington, Seattle 98105, USA.
J Endocrinol. 1997 Oct;155(1):79-86. doi: 10.1677/joe.0.1550079.
Growth hormone-releasing peptide (GHRP)-2 is a synthetic six amino acid peptide that is a potent GH secretagogue. Although it shares no structural homology with GH-releasing hormone, in clinical studies its actions on the pituitary release of GH are similar. It is effective when administered orally and intranasally. For children with GH deficiency, such noninvasive treatments are most desirable and in need of development. Fifteen children with short stature participated in this study. All of the children had a height < 2 S.D. below mean for age, poor height velocity, delayed bone age, and low serum concentrations of IGF-1. These children had been tested with standard GH secretagogues, e.g. arginine, insulin, and L-dopa. Fifty percent of the children were GH deficient, the remainder had idiopathic short stature. The children received testing with GHRH and GHRP-2 as an acute i.v. bolus of 1 microgram/kg; all children in this study demonstrated a GH response > 20 micrograms/l. Each child in this study also demonstrated a GH response > 10 micrograms/l in response to intranasal GHRP-2, in the dose range of 5-20 micrograms/kg. The children were administered intranasal GHRP-2, 5-15 micrograms/kg, twice a day for 3 months, then three times a day. Fifteen children participated in the study for 6 months; six of the children have participated for 18-24 months. Height velocity, serum IGF-1, IGF-binding protein 3 (IGFBP-3) and GH-binding protein (GHBP) concentrations, and GH responses to GHRP-2 by i.v. bolus and intranasal spray were examined during treatment. Height velocity increased from 3.7 +/- 0.2 cm/year to 6.1 +/- 0.3 cm/year at 6 months, 6.0 +/- 0.4 cm/year at 18-24 months. There were no significant changes in IGF-1 or IGF-PB3 concentrations, or in acute GH responses to i.v. or intranasal GHRP-2. GHBP concentrations rose significantly, from 439 +/- 63 pmol/l to 688 +/- 48 pmol/l. In this study, intranasal GHRP-2 administration was well tolerated, and produced a modest but significant increase in growth velocity.
生长激素释放肽(GHRP)-2是一种人工合成的六氨基酸肽,是一种强效的生长激素促分泌素。尽管它与生长激素释放激素没有结构同源性,但在临床研究中,它对垂体释放生长激素的作用相似。口服和鼻内给药时它都有效。对于生长激素缺乏的儿童来说,这种非侵入性治疗是最理想且急需开发的。15名身材矮小的儿童参与了这项研究。所有儿童的身高均低于年龄均值2个标准差,身高增长速度缓慢,骨龄延迟,且血清胰岛素样生长因子-1(IGF-1)浓度较低。这些儿童已经接受了标准生长激素促分泌素的测试,如精氨酸、胰岛素和左旋多巴。50%的儿童生长激素缺乏,其余儿童患有特发性矮小症。这些儿童接受了生长激素释放激素(GHRH)和GHRP-2的测试,静脉推注1微克/千克;本研究中的所有儿童生长激素反应均>20微克/升。本研究中的每个儿童对5-20微克/千克剂量范围内的鼻内GHRP-2反应时生长激素反应也>10微克/升。给儿童鼻内给予5-15微克/千克的GHRP-2,每天两次,持续3个月,然后每天三次。15名儿童参与该研究6个月;其中6名儿童参与了18-24个月。在治疗期间,检测了身高增长速度、血清IGF-1、胰岛素样生长因子结合蛋白3(IGFBP-3)和生长激素结合蛋白(GHBP)浓度,以及静脉推注和鼻内喷雾给予GHRP-2后的生长激素反应。6个月时身高增长速度从3.7±0.2厘米/年增加到6.1±0.3厘米/年,18-24个月时为6.0±0.4厘米/年。IGF-1或IGF-PB3浓度以及静脉或鼻内给予GHRP-2后的急性生长激素反应没有显著变化。GHBP浓度显著升高,从439±63皮摩尔/升升至688±48皮摩尔/升。在本研究中,鼻内给予GHRP-2耐受性良好,并使生长速度有适度但显著的增加。